

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul29pxo

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:25:23 ON 17 FEB 2009

```
=> file reg
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.22        0.22
```

FILE 'REGISTRY' ENTERED AT 08:25:33 ON 17 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 FEB 2009 HIGHEST RN 1107125-97-2
DICTIONARY FILE UPDATES: 16 FEB 2009 HIGHEST RN 1107125-97-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10720702a.str
```

L1 STRUCTURE UPLOADED

```
=> ld l1
LD IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).
```

```
=> d l1
L1 HAS NO ANSWERS
L1 STR
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

```
=>
Uploading C:\Program Files\Stnexp\Queries\10720702.str
```

L2 STRUCTURE UPLOADED

```
=> s l1
SAMPLE SEARCH INITIATED 08:27:11 FILE 'REGISTRY'
```

SAMPLE SCREEN SEARCH COMPLETED - 1057 TO ITERATE

100.0% PROCESSED 1057 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 19190 TO 23090
PROJECTED ANSWERS: 2 TO 124

L3 2 SEA SSS SAM L1

=> search l2
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:.
SAMPLE SEARCH INITIATED 08:27:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2497 TO ITERATE

80.1% PROCESSED 2000 ITERATIONS 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 46943 TO 52937
PROJECTED ANSWERS: 5 TO 273

L4 5 SEA SSS SAM L2

=> search l1
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 08:27:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 21651 TO ITERATE

100.0% PROCESSED 21651 ITERATIONS 78 ANSWERS
SEARCH TIME: 00.00.01

L5 78 SEA SSS FUL L1

=> search l2
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 08:27:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 49956 TO ITERATE

100.0% PROCESSED 49956 ITERATIONS 108 ANSWERS
SEARCH TIME: 00.00.01

L6 108 SEA SSS FUL L2

=> s l6 not l5
L7 30 L6 NOT L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	372.72	372.94

FILE 'CAPLUS' ENTERED AT 08:28:14 ON 17 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Feb 2009 VOL 150 ISS 8
FILE LAST UPDATED: 16 Feb 2009 (20090216/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 130

L30 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s 17

L8 10 L7

=> d 18 fbib ab hitstr 1-10

L8 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:16686 CAPLUS

DN 138:205004

TI Substituted Pyrazolopyridopyridazines as Orally Bioavailable Potent and Selective PDE5 Inhibitors: Potential Agents for Treatment of Erectile Dysfunction

AU Yu, Guixue; Mason, Helen; Wu, Ximao; Wang, Jian; Chong, Saeho; Beyer, Bruce; Henwood, Andrew; Pongrac, Ronald; Seliger, Laurie; He, Bin; Normandin, Diane; Ferrer, Pam; Zhang, Rongan; Adam, Leonard; Humphrey, William G.; Krupinski, John; Macor, John E.

CS Discovery Chemistry, Drug Metabolism and Pharmacokinetics, Princeton, NJ, 08543-5400, USA


SO Journal of Medicinal Chemistry (2003), 46(4), 457-460
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 138:205004
 AB Novel pyrazolopyridopyridazines, e.g. I, have been prepared as potent and selective PDE5 inhibitors. I has been identified as a more potent and selective PDE5 inhibitor than sildenafil. It is as efficacious as sildenafil in in vitro and in vivo PDE5 inhibition models, and it is orally bioavailable in rats and dogs. The superior isoenzyme selectivity of I is expected to exert less adverse effects in humans when used for erectile dysfunction treatment.
 IT 296248-82-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of substituted pyrazolopyridopyridazines as orally bioavailable selective PDE5 inhibitors for treatment of erectile dysfunction)
 RN 296248-82-3 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine, N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-(4-pyridinylmethyl)- (CA INDEX NAME)




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2000:688225 CAPLUS
 DN 133:252445
 TI Preparation of fused pyridopyridazine inhibitors of cGMP phosphodiesterase
 IN Yu, Guixue; Macor, John; Chung, Hyei-jha; Humora, Michael; Katipally, Kishta; Wang, Yizhe; Kim, Soojin
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056719	A1	20000928	WO 2000-US6100	20000309
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,			


	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
			US 1999-125488P	P 19990322
			US 1999-148009P	P 19990810
CA 2368023	A1	20000928	CA 2000-2368023	20000309
			US 1999-125488P	P 19990322
			US 1999-148009P	P 19990810
			WO 2000-US6100	W 20000309
EP 1165521	A1	20020102	EP 2000-916180	20000309
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
			US 1999-125488P	P 19990322
			US 1999-148009P	P 19990810
			WO 2000-US6100	W 20000309
AU 765128	B2	20030911	AU 2000-37327	20000309
			US 1999-125488P	P 19990322
			US 1999-148009P	P 19990810
			WO 2000-US6100	W 20000309
CN 1161341	C	20040811	CN 2000-805376	20000309
			US 1999-125488P	P 19990322
			US 1999-148009P	P 19990810
US 6316438	B1	20011113	US 2000-526162	20000315
			US 1999-125488P	P 19990322
			US 1999-148009P	P 19990810
OS	MARPAT 133:252445			
AB	The title compds. [I; Y = N, CR5; Z = N, CR6 (provided that at least one of Y and Z = N); R1, R2 = H, halo, SR7, etc.; R3 = H, alkyl, arylalkyl; R4 = H, halo, alkyl, etc.; R5, R6 = H, halo, alkyl; R7 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts, inhibitors of cGMP PDE, especially type 5, useful in treating cardiovascular and sexual disorders, were prepared E.g., a multi-step synthesis of I [Y = N; Z = CH; R1 = 4-hydroxypiperidin-1-yl; R2 = (3-Cl-4-MeOC6H3)CH2NH; R3 = Et; R4 = H] was given. Compds. I are effective at 0.05-100 mg/kg/day.			
IT	296248-82-3P 296248-95-8P 296249-08-6P 296249-10-0P 296249-11-1P 296249-30-4P 296249-33-7P 296249-43-9P 296249-44-0P 296249-48-4P 296249-59-7P 296249-62-2P 296249-68-8P 296249-79-1P 296249-80-4P 296249-84-8P 296249-85-9P 296249-87-1P 296250-40-3P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fused pyridopyridazine inhibitors of cGMP phosphodiesterase)			
RN	296248-82-3 CAPLUS			
CN	3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine, N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-(4-pyridinylmethyl)- (CA INDEX NAME)			




RN 296248-95-8 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N6,N9-bis[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 296249-08-6 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[(1-oxido-4-
 pyridinyl)methyl]- (CA INDEX NAME)




RN 296249-10-0 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-(2-pyridinylmethyl)- (CA
 INDEX NAME)



RN 296249-11-1 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-(3-pyridinylmethyl)- (CA
 INDEX NAME)




RN 296249-30-4 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[3-(4-methyl-1-
 piperazinyl)propyl]- (CA INDEX NAME)




RN 296249-33-7 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[2-(4-morpholinyl)ethyl]-

(CA INDEX NAME)




RN 296249-43-9 CAPLUS

CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
N9-[(3-chloro-4-methoxyphenyl)methyl]-N6-[(2,6-dichloro-4-
pyridinyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 296249-44-0 CAPLUS

CN Ethanone, 1-[4-[[[9-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-3-ethyl-3H-
pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazin-6-yl]amino]methyl]-1-
piperidinyl]- (CA INDEX NAME)




RN 296249-48-4 CAPLUS

CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 296249-59-7 CAPLUS

CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 296249-62-2 CAPLUS

CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 296249-68-8 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[2-(4-methyl-1-
 piperazinyl)ethyl]- (CA INDEX NAME)




RN 296249-79-1 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[[(2R)-tetrahydro-2-
 furanyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 296249-80-4 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[[(2S)-tetrahydro-2-
 furanyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 296249-84-8 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[3-(4-morpholinyl)propyl]-
 (CA INDEX NAME)




RN 296249-85-9 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[2-(1-piperidinyl)ethyl]-
 (CA INDEX NAME)




RN 296249-87-1 CAPLUS
 CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
 N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[2-(tetrahydro-2H-pyran-4-

yl)ethyl]- (CA INDEX NAME)



RN 296250-40-3 CAPLUS

CN 3H-Pyrazolo[4',3':5,6]pyrido[3,4-d]pyridazine-6,9-diamine,
N9-[(3-chloro-4-methoxyphenyl)methyl]-3-ethyl-N6-[2-(1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1983:612481 CAPLUS

DN 99:212481

OREF 99:32699a,32702a

TI Condensed pyridazines. I. Reaction of
5,8-dichloropyrido[2,3-d]pyridazine with carbanion

AU Oishi, Etsuo; Watanabe, Hiromi; Hayashi, Eisaku

CS Shizuoka Coll. Pharm., Shizuoka, 422, Japan

SO Yakugaku Zasshi (1983), 103(6), 623-30

CODEN: YKKZAJ; ISSN: 0031-6903


DT Journal

LA Japanese


OS CASREACT 99:212481

AB Reaction of the title compound I (R = R1 = Cl) (II) with EtO2CCH2CN,
MeCOCH2CO2Et, CH2(CO2Et)2, CH2(CN)2, and PhCH2CN in C6H6 in the presence
of NaNH2 gave I [R = EtO2CCHCN, CH(CN)2; R1 = Cl] and I [R = Cl; R1 =
EtO2CCHCN, CH2CO2Et, CH(CO2Et)2, PhCHCN]. II reacted with MeCOPh and
EtCOPh in PhMe in the presence of NaH to give I (R = R1 = CH2COPh; R = Cl,


R1 = CH₂COPh; R = Cl, R1 = CHMeCOPh).
 IT 87950-34-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 87950-34-3 CAPLUS
 CN Ethanone, 2,2'-pyrido[2,3-d]pyridazine-5,8-diylbis[1-phenyl- (9CI) (CA
 INDEX NAME)




L8 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1976:586482 CAPLUS
 DN 85:186482
 OREF 85:29744h,29745a
 TI Structure-activity relations of the diuretic activity of triaza- and
 tetraazanaphthalene compounds
 AU Nishikawa, Kohei; Shimakawa, Hisao; Inada, Yoshiyuki; Shibouta, Yumiko;
 Kikuchi, Shintaro; Yurugi, Shojiro; Oka, Yoshikazu
 CS Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, Japan
 SO Chemical & Pharmaceutical Bulletin (1976), 24(9), 2057-77
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 AB The diuretic activity of 219 nitrogen containing heterocyclic compds.,
 classified into 13 groups based on the structural features, was studied in
 saline loaded rats. Of the compds. studied, 104 were active at oral doses
 of 10-30 mg/kg. Several of the pyrimidopyridazines, pyridazinopyridazines
 and pyridopyridazines produced as potent diuresis and natriuresis as
 hydrochlorothiazide [58-93-5] at the oral dose of 0.1 mg/kg; DS 210 (I)
 [33222-18-3] and DS 511 (II) [39632-88-7] were selected for more extensive
 evaluation as diuretic agents. Structure-activity relations of the tested
 compds. are discussed.
 IT 33222-21-8 39632-89-8 61098-88-2
 RL: BIOL (Biological study)
 (diuretic)
 RN 33222-21-8 CAPLUS
 CN Pyrimido[4,5-d]pyridazine-5,8-diamine, 2-phenyl-N5,N8-bis(phenylmethyl)-
 (CA INDEX NAME)



RN 39632-89-8 CAPLUS
 CN Pyrido[3,4-d]pyridazine-1,4-diamine, 7-phenyl-N1,N4-bis(phenylmethyl)-
 (CA INDEX NAME)



RN 61098-88-2 CAPLUS
 CN Pyrido[2,3-d]pyridazine-5,8-diamine, 2-phenyl-N5,N8-bis(phenylmethyl)-
 (CA INDEX NAME)




L8 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1976:17256 CAPLUS
 DN 84:17256
 OREF 84:2855a,2858a
 TI Syntheses of N-heterocyclic compounds. XXV. Syntheses of
 pyrido[3,4-d]pyridazine derivatives. 2
 AU Oka, Yoshikazu; Omura, Kiyoshi; Miyake, Akio; Itoh, Katsumi; Tomimoto,
 Mitsumi; Tada, Norio; Yurugi, Shojiro
 CS Med. Res. Lab., Takeda Chem. Ind., Ltd., Osaka, Japan
 SO Chemical & Pharmaceutical Bulletin (1975), 23(10), 2239-50
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 OS CASREACT 84:17256

AB Twenty-nine derivs. of the potent diuretic
 1,4-dimorpholino-7-phenylpyrido[3,4-d]pyridazine, e.g., I (R = Ph, Me-,
 Cl-, O₂N-, and MeOC₆H₄, xylyl, 2-furyl, 2-pyridyl, 1-, 2-naphthyl; R₁ = H,
 Me, PhCH₂; R₂ = morpholino, piperidino, pyrrolidino), were prepared. In
 1,4-dichloropyrido[3,4-d]pyridazine the 4-chloro group was more reactive
 toward nucleophilic substitution than the 1-chloro group. Some reaction
 of I, e.g. acid hydrolysis, reduction and Grignard addition reaction were also
 carried out. Significance of the ring N at the 6-position in I for
 diuretic activity is discussed.

IT 57961-44-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 57961-44-1 CAPLUS

CN Pyrido[3,4-d]pyridazine, 7-phenyl-1,4-bis[(phenylmethyl)thio]- (CA INDEX
 NAME)



L8 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1973:58358 CAPLUS

DN 78:58358

OREF 78:9259a,9262a

TI Syntheses of N-heterocyclic compounds. IX. Reduction of
 2-aryl-5,8-disubstituted pyrimido[4,5-d]pyridazine

AU Yurugi, Shojiro; Fushimi, Tomiyoshi; Hieda, Masaru

CS Res. Dev. Div., Takeda Chem. Ind., Ltd., Osaka, Japan

SO Yakugaku Zasshi (1972), 92(11), 1316-21
 CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal


LA Japanese

AB Reduction of 2-aryl-5,8-disubstituted pyrimido[4,5-d]pyridazine ((I) (R =
 iso-PrNH, PhNH, PhCH₂NH, piperidino, morpholino, etc.; R₁ = Ph, m-tolyl,
 p-ClC₆H₄, 2-thienyl, 5-morpholino-2-furyl)) to
 2-aryl-3,4-dihydro-5,8-disubstituted-pyrimido[4,5-d]pyridazine (II) was
 carried out with NaBH₄, LiAlH₄, sodium isopentoxide, and a catalyst.
 Acylation of II gave 2-aryl-3-acyl-3,4-dihydro-5,8-
 dimorpholinopyrimido[4,5-d]pyridazine and alkylation of II gave
 2-aryl-3-alkyl-3,4-dihydro-5,8-dimorpholinopyrimido[4,5-d]pyridazine.
 2-Aryl-5,8-disubstituted-3,4-dihydropyrimido-[4,5-d]pyridazines showed a
 strong diuretic activity.


IT 33222-21-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reduction of)

RN 33222-21-8 CAPLUS


CN Pyrimido[4,5-d]pyridazine-5,8-diamine, 2-phenyl-N5,N8-bis(phenylmethyl)-
 (CA INDEX NAME)



L8 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1973:43400 CAPLUS
 DN 78:43400
 OREF 78:6863a,6866a
 TI Syntheses of N-heterocyclic compounds. XII. Syntheses of
 pyrido[3,4-d]pyridazine and pyrido[2,3-d]pyridazine derivatives
 AU Yurugi, Shojiro; Fushimi, Tomiyoshi; Sugihara, Hirosada; Hieda, Masaru
 CS Res. Dev. Div., Takeda Chem. Ind., Ltd., Osaka, Japan
 SO Yakugaku Zasshi (1972), 92(11), 1333-8
 CODEN: YKKZAJ; ISSN: 0031-6903
 DT Journal
 LA Japanese
 AB 1,2,3,4-Tetrahydro-7-phenylpyrido[3,4-d]pyridazine-1,4-dione (I) and
 2-phenyl-5,6,7,8-tetrahydropyrido[2,3-d]pyridazine-5,8-dione (II) were
 converted to the corresponding dichlorides, which reacted with amines to
 give 1,4-bis(substituted amino)-7-phenylpyrido[3,4-d]pyridazines and
 2-phenyl-5,8-bis-(substituted amino)pyrido[2,3-d]pyridazines.
 1,4-Dimorpholino-7-phenylpyrido[3,4-d]pyridazine and
 2-phenyl-5,8-bis(isopropylamino)pyrido[2,3-d]pyridazine were diuretics.
 IT 39632-89-8P 39632-90-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 39632-89-8 CAPLUS
 CN Pyrido[3,4-d]pyridazine-1,4-diamine, 7-phenyl-N1,N4-bis(phenylmethyl)-
 (CA INDEX NAME)




RN 39632-90-1 CAPLUS
 CN Pyrido[2,3-d]pyridazine-5,8-diamine, 2-phenyl-N5,N8-bis(phenylmethyl)-,
 hydrochloride (1:1) (CA INDEX NAME)




● HCl

L8 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1972:514340 CAPLUS
 DN 77:114340
 OREF 77:18841a,18844a
 TI Synthesis of N-heterocyclic compounds. VII. 2-Aryl-5,8-disubstituted pyrimido[4,5-d]pyridazine
 AU Yurugi, Shojiro; Hieda, Masaru; Fushimi, Tomiyoshi; Kawamatsu, Yutaka; Sugihara, Hirosada; Tomimoto, Mitsumi
 CS Res. Dev. Div., Takeda Chem. Ind., Ltd., Osaka, Japan
 SO Chemical & Pharmaceutical Bulletin (1972), 20(7), 1528-35
 CODEN: CPBTAL; ISSN: 0009-2363
 DT Journal
 LA English
 AB When 2-aryl-5,8-dichloropyrimido[4,5-d]pyridazine (I, R = R1 = Cl) was reacted with nucleophiles, such as amines, sodium methoxide, sodium azide, sodium sulfide etc., 5,8-disubstituted I (R = R1 = PrNH, MeS, morpholino, etc. Ar = Ph, MeC6H4, 2-pyridyl, etc.) were obtained. treatment of 2-phenyl-5-chloro-8-morpholinopyrimido-[4,5-d]pyridazine or 2-phenyl-5-morpholino-8-chloropyrimido-[4,5-d]pyridazine with nucleophiles gave I (R = R1). The phenyl group at the 2-position accelerated the substitution at position 5 and 8. The reaction of 2-phenyl-5,8-bis(substituted thio)pyrimido[4,5-d]pyridazine with Cl gave I (R = R1 = Cl, Ar = Ph). Several compds. showed diuretic activity.
 IT 33222-21-8P 38277-18-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 33222-21-8 CAPLUS
 CN Pyrimido[4,5-d]pyridazine-5,8-diamine, 2-phenyl-N5,N8-bis(phenylmethyl)-
 (CA INDEX NAME)



RN 38277-18-8 CAPLUS
 CN Pyrimido[4,5-d]pyridazine, 2-phenyl-5,8-bis[(phenylmethyl)thio]- (CA
 INDEX NAME)



L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1971:476832 CAPLUS

DN 75:76832

OREF 75:12171a,12174a

TI Pyrimido[4,5-d]pyridazine derivatives

IN Yurugi, Shojiro; Kikuchi, Shintaro

PA Takeda Chemical Industries, Ltd.

SO Ger. Offen., 33 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2046577	A	19710506	DE 1970-2046577	19700922
				JP 1969-76125	A 19690924
				JP 1970-54984	A 19700624
	JP 48011116	B	19730410	JP 1970-54984	19700624
	NL 7014065	A	19710326	NL 1970-14065	19700923
				JP 1969-76125	A 19690924
				JP 1970-54984	A 19700624
	FR 2070085	A5	19710910	FR 1970-34490	19700923
	FR 2070085	B1	19750606		
				JP 1969-76125	A 19690924
	SE 363831	B	19740204	SE 1970-12956	19700923
				JP 1969-76125	A 19690924
				JP 1970-54984	A 19700624
	HU 164522	B	19740228	HU 1970-TA1090	19700923
				JP 1969-76125	A 19690924
				JP 1970-54984	A 19700624
	NO 129907	B	19740610	NO 1970-3617	19700923
				JP 1969-76125	A 19690924
				JP 1970-54984	A 19700624
	PL 81368	B1	19750830	PL 1970-143378	19700923
				JP 1969-76125	A 19690924
				JP 1970-54984	A 19700624
	AT 299218	B	19720612	AT 1970-8633	19700924
				JP 1969-76125	A 19690924
				JP 1970-54984	A 19700624
	DK 125472	B	19730226	DK 1970-4879	19700924
				JP 1969-76125	A 19690924

GB 1325769	A	19730808	JP 1970-54984	A 19700624
			GB 1970-45525	19700924
			JP 1969-76125	A 19690924
GB 1325770	A	19730808	JP 1970-54984	A 19700624
			GB 1973-11962	19700924
			JP 1969-76125	A 19690924
US 3764598	A	19731009	JP 1970-54984	A 19700624
			US 1970-75294	19700924
			JP 1969-76125	A 19690924
CH 547298	A	19740329	JP 1970-54984	A 19700624
			CH 1970-14165	19700924
			JP 1969-76125	A 19690924
CA 955941	A1	19741008	JP 1970-54984	A 19700624
			CA 1970-94012	19700924
			JP 1969-76125	A 19690924
FR 2108518	A5	19720519	JP 1970-54984	A 19700624
			FR 1971-34438	19710924
			AT 1970-8633	A 19700924

AB The diuretic title compds. (I) were prepared in a five-step reaction. Thus, benzamidine hydrochloride and [(ethylethoxy)methylene]oxalacetate were condensed in MeOH with MeONa to give 2-phenyl-4,5-bis(ethoxycarbonyl)pyrimidine, which was refluxed with NH₂NH₂·H₂O in MeOH to give I (R₁ = Ph, R₂ = ONH₂NH₃, R₃ = OH) (II). II in aqueous HCl was stirred at room temperature to give I (R₁ = Ph, R₂ = R₃ = OH)


(III). A mixture of III, POCl₃, and PCl₅ was heated 3 hr to give I (R₁ = Ph, R₂ = R₃ = Cl), was heated with morpholine for 3 hr at 80-5° to give I (R₁ = Ph, R₂ = R₃ = morpholino). Similarly prepared were .apprx.15 more I (R₂ = R₃ = aminosubstituted) and their corresponding intermediates.

IT 33222-21-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 33222-21-8 CAPLUS

CN Pyrimido[4,5-d]pyridazine-5,8-diamine, 2-phenyl-N₅,N₈-bis(phenylmethyl)-
(CA INDEX NAME)



L8 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1967:37890 CAPLUS

DN 66:37890

OREF 66:7227a,7230a

TI The synthesis of pyrazino[2,3-d]pyridazine and some of its derivatives


AU Patel, Natubhai R.; Castle, Raymond N.

CS Univ. of New Mexico, Albuquerque, NM, USA

SO Journal of Heterocyclic Chemistry (1966), 3(4), 512-17


CODEN: JHTCAD; ISSN: 0022-152X

DT Journal
 LA English
 AB Pyrazino[2,3-d]pyridazine (I) was synthesized by two different routes. 5,8-Dihydroxypyrazino-[2,3-d]pyridazine was converted to 5,8-Dihydroxypyrazino-[2,3-d]pyridazine (II) and 5,8-dibromopyrazino[2,3-d]pyridazine. When II was treated with various benzyl mercaptans and alk-oxides the corresponding disubstituted drives. were obtained. II when allowed to react with aromatic amines gave 5,8-diaminopyrazino[2,3-d]pyridazines; however, with aliphatic amines only mono-substituted products were obtained substituted in the 8-position. The reaction of pyrazine-2,3-dinitrile with hydrazine gave 5,8-diaminopyrazino[2,3-d]pyridazine.
 IT 13480-47-2P 13480-48-3P 13480-49-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 13480-47-2 CAPLUS
 CN Pyrazino[2,3-d]pyridazine, 5,8-bis[(phenylmethyl)thio]- (CA INDEX NAME)




RN 13480-48-3 CAPLUS
 CN Pyrazino[2,3-d]pyridazine, 5,8-bis[[4-chlorophenyl)methyl]thio]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 13480-49-4 CAPLUS
CN Pyrazino[2,3-d]pyridazine, 5,8-bis[[(3,4-dichlorophenyl)methyl]thio]- (CA
INDEX NAME)

PAGE 1-A



PAGE 2-A



=>